AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
14th May 2026 Uncategorised 0Following an FDA approval in muscle-invasive bladder cancer patients who are eligible to receive cisplatin-based chemotherapy, AstraZeneca on Thursday reported positive phase 3 results for its Imfinzi, used alongside Padcev, in those who were cisplatin-ineligible.
More: AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
Source: fierce